4.7 Article

Multi-dimensional target profiling of N,4-diaryl-1,3-thiazole-2-amines as potent inhibitors of eicosanoid metabolism

期刊

EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
卷 84, 期 -, 页码 302-311

出版社

ELSEVIER FRANCE-EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER
DOI: 10.1016/j.ejmech.2014.07.025

关键词

Cancer; Cardiovascular diseases; Cyclooxygenase; Inflammation; 5-Lipoxygenase; Thiazole-2-amines

资金

  1. Else Kroner-Fresenius-Stiftung
  2. LOEWE OSF
  3. Fonds der Chemischen Industrie
  4. Translational Research Innovation - Pharma (TRIP)
  5. Fraunhofer-Projektgruppe fur Translationale Medizin und Pharmakologie (TMP)
  6. Deutsche Forschungsgemeinschaft DFG [SFB 1039, Sachbeihilfe PR1405/2-1]
  7. European COST Actions [BM1007, CM1103, CM1207]

向作者/读者索取更多资源

Eicosanoids like leukotrienes and prostaglandins play a considerable role in inflammation. Produced within the arachidonic acid (AA) cascade, these lipid mediators are involved in the pathogenesis of pain as well as acute and chronic inflammatory diseases like rheumatoid arthritis and asthma. With regard to the lipid cross-talk within the AA pathway, a promising approach for an effective anti-inflammatory therapy is the development of inhibitors targeting more than one enzyme of this cascade. Within this study, thirty N-4-diaryl-1,3-thiazole-2-amine based compounds with different substitution patterns were synthesized and tested in various cell-based assays to investigate their activity and selectivity profile concerning five key enzymes involved in eicosanoid metabolism (5-, 12-, 15-lipoxygenase (LO), cyclooxygenase-1 and -2 (COX-1/-2)). With compound 7, 2-(4-phenyl)thiazol-2-ylamino)phenol (ST-1355), a multi-target ligand targeting all tested enzymes is presented, whereas compound 9, 2-(4-(4-chlorophenyethiazol-2-ylamino)phenol (ST-1705), represents a potent and selective 5-LO and COX-2 inhibitor with an IC50 value of 0.9 +/- 0.2 mu M (5-LO) and a residual activity of 9.1 +/- 1.1% at 10 mu M (COX-2 product formation). The promising characteristics and the additional non-cytotoxic profile of both compounds reveal new lead structures for the treatment of eicosanoid-mediated diseases. (C) 2014 Elsevier Masson SAS. All rights reserved.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据